COVID Vaccine Responses During Sibeprenlimab Treatment of IgA Nephropathy (IgAN): A Preliminary Analysis
June 15, 2023 | 60th ERA Congress
COVID Vaccine Responses During Sibeprenlimab Treatment of IgA Nephropathy (IgAN): A Preliminary Analysis
Strategies For Development Of Interleukin-2 Therapy In Transplant Recipients: What Works And What Doesn’t
June 3, 2023 | American Transplant Congress
Strategies For Development Of Interleukin-2 Therapy In Transplant Recipients: What Works And What Doesn’t
A Novel IL-2 Mutein Induces Regulatory T Cell-Rich Microenvironment and Leads to Alloantigen-Specific Graft Acceptance
June 3, 2023 | American Transplant Congress
A Novel IL-2 Mutein Induces Regulatory T Cell-Rich Microenvironment and Leads to Alloantigen-Specific Graft Acceptance
Selective Regulatory T-Cell Expansion by A Novel IL-2 Mutein in Murine Transplant and Humanized NSG Models
June 3, 2023 | American Transplant Congress 2023
Selective Regulatory T-Cell Expansion by A Novel IL-2 Mutein in Murine Transplant and Humanized NSG Models
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients with Immunoglobulin A Nephropathy (IgAN)
November 5, 2022 | American Society of Nephrology (ASN) Kidney Week
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients with Immunoglobulin A Nephropathy (IgAN)
Interim Analysis (IA) of a Global Phase 2 Randomized Controlled Trial of Sibeprenlimab (VIS649), an APRIL-Neutralizing Monoclonal Antibody, in IgA Nephropathy
November 3, 2022 | American Society of Nephrology (ASN) Kidney Week
Interim Analysis (IA) of a Global Phase 2 Randomized Controlled Trial of Sibeprenlimab (VIS649), an APRIL-Neutralizing Monoclonal Antibody, in IgA Nephropathy
Role of APRIL in IgAN Pathophysiology
October 4, 2022 | Rare & Genetic Kidney Disease Drug Development Conference
Role of APRIL in IgAN Pathophysiology
Role of Complement Cascade in Glomerular Diseases
October 4, 2022 | Rare & Genetic Kidney Disease Drug Development Conference
Role of Complement Cascade in Glomerular Diseases
A potent anti-C5aR1 Antibody for Treatment of ANCA Associated Vasculitis
September 27, 2022 | Complement-based Drug Development Summit
A potent anti-C5aR1 Antibody for Treatment of ANCA Associated Vasculitis
Brief Human IL-2 Mutein Therapy Induces Foxp3+ T-Regulatory Cell Expansion and Donor-Specific Allograft Tolerance
June 4, 2022 | American Transplant Congress
Brief Human IL-2 Mutein Therapy Induces Foxp3+ T-Regulatory Cell Expansion and Donor-Specific Allograft Tolerance
- 1
- 2
- 3
- 4
- Next Page »
